Neuro-oncology
News
Bevacizumab fails to improve survival in newly diagnosed glioblastoma
Major finding: Two similar studies found no difference in median survival with the addition of bevacizumab to standard therapy for patients with...
Conference Coverage
New chemo regimen is active against recalcitrant neuroendocrine tumors
Major finding: The overall response rate was 43% and the clinical benefit rate was 97%. Data source: A randomized phase II trial among 28 patients...
News
Gene panel identifies residual neuroblastoma metastases
Major finding: In a multivariate analysis, patients negative for minimal residual disease had about a fourfold increased rate of progression-free...
News
CENTRIC results signal end of cilenglitide in glioblastoma
Major finding: Overall survival was 26.3 months in both study arms, and more events occurred in the cilenglitide arm than in the control arm (144...
Conference Coverage
Younger adults with brain metastases survive longer with radiosurgery alone
Major finding: Stereotactic radiosurgery was associated with significantly longer overall survival among patients age 50 years and younger (hazard...
News
Study indicates potential for longer survival after radiosurgery for brain metastases
Major finding: Median overall survival for patients with brain metastases from non–small cell lung cancer was 9.0 months for those treated with...
News
Spare the hippocampus, preserve the memory in whole brain irradiation
Major finding: Patients who underwent whole brain radiation therapy with hippocampal avoidance had a 7% decline in delayed recall at 4 months,...
Conference Coverage
Prolactin measure didn’t help localize pituitary adenoma
Major finding: The unadjusted and prolactin-adjusted ACTH intersinus ratios correctly localized 18 of 26 lateral pituitary adenomas (69%),...
News
Good survival rates with temozolomide CRT for high-risk, low-grade gliomas
Major finding: With temozolomide chemoradiotherapy, 3-year overall survival was 73% for patients with low-grade gliomas and three or more risk...
Conference Coverage
Donepezil fails to improve cognition after brain irradiation
Major finding: There were no significant differences between donepezil or placebo in either cognitive composite scores after 12 or 24 weeks of...
News
Frontline bevacizumab fails to boost glioblastoma survival in key trials
Major finding: Median overall survival for those assigned to radiation, temozolomide, and placebo was 16.1 months, vs.